Abstract
Cancer is a lethal disease, and its therapy should be tailed to individual patients by functional imaging to optimize therapy strategies. Single-photon emission computed tomography (SPECT) is a quantitative functional imaging modality used by oncologists to monitor tumor response. SPECT can track therapy-induced biological and metabolic changes in tumors; such changes usually precede anatomical alterations. Assessment of treatment response using SPECT tracers may result in modifications in treatment planning and predicting the long-term outcome. These SPECT tracers can be classified into metabolism, cell surface receptor, intracellular receptor, microenvironment, and apoptosis tracers. The most widely used SPECT tracers include 201Tl-thallium chloride, 67Ga-gallium citrate, 123I/131I-sodium iodide, 99mmTc-MIBI, 99mTc-MDP, and 123I/131I –MIBG. Apoptosis tracers, which can directly monitor early tumor response in cancer patients and can predict the outcome, have attracted increasing attention in the field of oncology. Annexin V-based SPECT tracers, including 99mTc-BTAP-annexin V, 99mTc-HYNIC-annexin-V, 99mTc-EC-annexin-V, 99mTc-i-annexin V, and 123I-annexin V, have been evaluated in clinical trials. Novel SPECT tracers, such as radiolabeled small molecules, aptamers, peptides, and proteins, need to be explored in the future to further improve the outcome of cancer therapy. In this review, SPECT tracers used to predict and monitor cancer therapy in both preclinical and clinical settings are summarized. Some tracers may contribute to the improvement of cancer therapy management.
Keywords: Cancer therapy, Evaluation, Prediction, SPECT, Tracer.
Current Pharmaceutical Biotechnology
Title:Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Volume: 14 Issue: 7
Author(s): Jiong Cai and Fang Li
Affiliation:
Keywords: Cancer therapy, Evaluation, Prediction, SPECT, Tracer.
Abstract: Cancer is a lethal disease, and its therapy should be tailed to individual patients by functional imaging to optimize therapy strategies. Single-photon emission computed tomography (SPECT) is a quantitative functional imaging modality used by oncologists to monitor tumor response. SPECT can track therapy-induced biological and metabolic changes in tumors; such changes usually precede anatomical alterations. Assessment of treatment response using SPECT tracers may result in modifications in treatment planning and predicting the long-term outcome. These SPECT tracers can be classified into metabolism, cell surface receptor, intracellular receptor, microenvironment, and apoptosis tracers. The most widely used SPECT tracers include 201Tl-thallium chloride, 67Ga-gallium citrate, 123I/131I-sodium iodide, 99mmTc-MIBI, 99mTc-MDP, and 123I/131I –MIBG. Apoptosis tracers, which can directly monitor early tumor response in cancer patients and can predict the outcome, have attracted increasing attention in the field of oncology. Annexin V-based SPECT tracers, including 99mTc-BTAP-annexin V, 99mTc-HYNIC-annexin-V, 99mTc-EC-annexin-V, 99mTc-i-annexin V, and 123I-annexin V, have been evaluated in clinical trials. Novel SPECT tracers, such as radiolabeled small molecules, aptamers, peptides, and proteins, need to be explored in the future to further improve the outcome of cancer therapy. In this review, SPECT tracers used to predict and monitor cancer therapy in both preclinical and clinical settings are summarized. Some tracers may contribute to the improvement of cancer therapy management.
Export Options
About this article
Cite this article as:
Cai Jiong and Li Fang, Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy, Current Pharmaceutical Biotechnology 2013; 14 (7) . https://dx.doi.org/10.2174/1389201014666131226105651
DOI https://dx.doi.org/10.2174/1389201014666131226105651 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sentinel Node Imaging
Current Medical Imaging Death Receptor Ligands: New Strategies for Combined Treatment with Ionizing Radiation
Current Medicinal Chemistry - Anti-Cancer Agents 4,7-Dihydroindole: A Synthon for the Preparations of 2-Substituted Indoles
Current Organic Synthesis Surgical Approach to Ulcerative Colitis: When is the Best Timing after Medical Treatment?
Current Drug Targets Potent Chemopreventive Agents Against Pancreatic Cancer
Current Cancer Drug Targets Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Reducing False Positive Findings in Statistical Analysis of Pharmacogenomic Biomarker Studies Using High-Throughput Technologies
Current Drug Safety Biomaterial and Stem Cell Interactions: Histological Biocompatibility
Current Stem Cell Research & Therapy Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets Probiotics and Different Efficacy, How it can be Managed?
Current Drug Therapy Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
Current Drug Targets Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Advances on PPARγ Research in the Emerging Era of Precision Medicine
Current Drug Targets Expression Microarray Proteomics and the Search for Cancer Biomarkers
Current Genomics Biofunctional Materials for Directing Vascular Development
Current Vascular Pharmacology Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design